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Abstract 
Pseudomyogenic hemangioendothelioma (PMH) is a recently described, indolent vascular tumor that usually presents 
in the distal extremities. PMH typically has a multi‑focal presentation and can involve several tissue planes including 
the dermis, subcutis, muscle, and bone. This soft tissue tumor predominantly affects men between 20 and 50 years 
of age. PMH tumors typically are resected but frequently recur locally; thus, more efficacious treatment options are 
needed. Herein, we report two cases of patients with PMH who were treated with systemic therapy. To the best of our 
knowledge, our report is the first to describe a response of PMH either to gemcitabine/taxane cytotoxic chemother‑
apy or to a mammalian target of rapamycin inhibitor. In the first case, a 45‑year‑old man with PMH of the right ilium 
was treated with gemcitabine plus docetaxel. Although chemotherapy was ultimately halted owing to gemcitabine‑
induced pulmonary toxicity, positron emission tomography‑computer tomography scans taken after three cycles 
of gemcitabine plus docetaxel illustrated a noticeable response to the regimen. In the second case, a 22‑year‑old 
man with PMH of the right distal femur and metastases in the left ilium showed no response to gemcitabine plus 
docetaxel therapy, but underwent surgical resection after cisplatin and doxorubicin resulted in stable disease. DNA 
sequencing of his tumor revealed the presence of a tuberous sclerosis 1 (TSC1) mutation, so daily everolimus, which 
inhibits mammalian target of rapamycin, was started. Two months after beginning everolimus, the patient underwent 
magnetic resonance imaging of the pelvis, which revealed mild shrinkage of PMH metastases in the left iliac bone. 
Despite the apparent heterogeneity of response to gemcitabine/taxane chemotherapy in our two patients, these two 
cases indicate that gemcitabine/taxane and mammalian target of rapamycin inhibitor may serve as systemic treat‑
ment options for PMH and warrant further investigation.
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Background
Pseudomyogenic hemangioendothelioma (PMH) is a 
rare indolent vascular tumor that typically presents in 
the distal extremities and may present in multiple tissue 
planes, including the dermis, subcutis, muscle, and bone 
[1, 2]. Over the last three decades, PMH has been deter-
mined to be the same pathological entity as epithelioid 
sarcoma-like hemangioendothelioma and fibroma-like 
variant of epithelioid sarcoma [2–5]. The tumor has a 
4.6:1 male predominance and typically occurs in men 
between 20 and 50  years of age. Histopathologically, 
PMH resembles a myogenic neoplasm with a striking 
rhabdomyoblast appearance and spindle cell morphol-
ogy. However, PMH lacks true muscle markers such as 
desmin and has an immunophenotype and highly mem-
branous pattern in line with endothelial differentiation 
[2, 5]. PMH has recently been characterized molecu-
larly to have a balanced t(7;19) translocation resulting in 
a SERPINE1-FOSB fusion [6]. PMH does not typically 
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transform into high-grade disease or metastasize. How-
ever, PMH frequently recurs locally after excision [2].
While much has been published concerning the char-
acterization of PMH, much remains to be learned about 
the natural history of the disease and efficacy of treat-
ment. In the majority of PMH cases, excision is the man-
agement modality of choice, but over a third of patients 
experience local recurrence or new nodules in adjacent 
soft tissue during follow up [2]. Previous accounts dem-
onstrate an indolent course of disease and most studies 
have shown that the disease does not progress before 
or after therapy. In a large case series (n = 50), only one 
patient died of PMH. Nevertheless, since PMH presents 
as multifocal tumors in 70 % of patients, systemic therapy 
options are acutely needed [2].
To the best of our knowledge, only two published 
reports [5, 7] in the literature discuss a response by PMH 
to therapeutic options other than excision.
Here, we report two cases of patients who had PMH 
that responded to systemic therapy: one patient exhibited 
a noticeable response to gemcitabine plus docetaxel and 
one patient demonstrated a response to everolimus, a 
mammalian target of rapamycin (mTOR) inhibitor.
Case presentation
Case 1
In October 2010, a 45-year-old man presented to his 
local physician with pain in his right groin, which the 
patient attributed to a muscle strain from playing soccer. 
As his pain worsened, the patient went to an orthopedic 
surgeon who obtained a magnetic resonance imaging 
(MRI) study that showed a mass within the right anterior 
ilium. In December 2010, the patient was examined by 
physicians in the Department of Orthopaedic Oncology 
at The University of Texas MD Anderson Cancer Center, 
and a biopsy of the right ilium mass revealed a malig-
nant epithelioid and spindle cell neoplasm most consist-
ent with PMH. The patient was treated with two cycles 
of intra-arterial cisplatin (120 mg/m2) administered every 
3 weeks. Due to hearing loss, administration was modi-
fied to intravenously with a slow infusion rate over 24 h 
for the next two cycles. Restaging positron emission 
tomography-computed tomography (PET-CT) studies 
revealed a minor tumor response to cisplatin.
Because the patient’s hearing loss worsened, therapy 
was switched to a combination of gemcitabine (900 mg/
m2) and docetaxel (100  mg/m2) administered in 3  week 
cycles, beginning 3  weeks after cessation of cisplatin. 
Restaging PET-CT studies performed after completion 
of the third cycle revealed that the PMH had significantly 
responded to gemcitabine plus docetaxel (Fig. 1). Unfor-
tunately, despite this significant improvement, there was 
evidence of gemcitabine-induced pulmonary toxicity. 
Therefore, cytotoxic chemotherapy was halted, and a 
tapering dose of steroids was given to the patient to treat 
the pulmonary toxicity. The patient’s edema was man-
aged with furosemide and amiloride.
During a follow-up visit 3  months after cessation of 
gemcitabine and docetaxel, the patient’s PET-CT scans 
showed mild progression of disease in the right iliac bone 
with enlarging lucencies. This finding suggested that the 
PMH progressed in the absence of gemcitabine and doc-
etaxel treatment. Therapy with weekly paclitaxel (80 mg/
m2) was therefore started. However, after 4  months of 
paclitaxel, therapy was discontinued because the patient 
experienced hearing loss, rhinitis, and neuropathy char-
acterized by tingling of the hands and feet. Restaging 
studies performed 16 months following cessation of cyto-
toxic chemotherapy revealed stable disease.
The tumor response to the combination of gemcitabine 
and a taxane was clearly demonstrated on the PET-CT 
scans. PMH progressed once chemotherapy was stopped, 
and taxane treatment led to disease stability, suggesting 
that gemcitabine plus taxane could be an effective treat-
ment for PMH.
Case 2
In June 2011, a 22-year-old man presented to his local 
physician with a painless, dime-shaped nodule in his 
right lateral thigh. Approximately 1  year later, the mass 
began to enlarge and induce pain, and the patient saw a 
dermatologist who performed a punch biopsy that was 
inconclusive. In September 2012, an excisional biopsy 
was performed at MD Anderson Cancer Center, and the 
pathologist concluded that the mass was consistent with 
PMH originating from the right femur. Baseline imaging 
included MRI of the right thigh which showed multiple 
enhancing lesions in the distal right femur and lateral 
soft tissues, extending for a length of 6.8  cm and cen-
tered approximately 7  cm proximal to the articular sur-
face of the lateral femoral condyle. A baseline PET-CT 
study revealed a hypermetabolic mass in the right distal 
femur (standardized uptake value, maximum of 15.2) and 
a 1.3 cm left acetabular lytic lesion (standardized uptake 
value, maximum of 7.9), suspicious for metastatic dis-
ease (Fig.  2). After the patient was evaluated by physi-
cians in the Department of Sarcoma Medical Oncology 
at MD Anderson, therapy with gemcitabine (900  mg/
m2) and docetaxel (75  mg/m2) was started and given in 
3 week cycles. The cytotoxic chemotherapy was well tol-
erated. However, imaging showed no evidence of tumor 
response after two cycles, and treatment was halted.
Therapy was then changed to doxorubicin (90  mg/
m2 as a continuous infusion over 72  h) and cisplatin 
(120  mg/m2 as an intravenous infusion over 4  h), but 
the patient had mucositis, tinnitus, neutropenic fever, 
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and ototoxicity during the first cycle. The cisplatin dose 
was reduced to 100 mg/m2 as a slow infusion over 24 h 
to prevent ototoxicity and doxorubicin was changed to 
bolus doxorubicin with dexrazoxane (90  mg/m2) in a 
3  week cycle to reduce mucositis caused by continuous 
intravenous infusion of doxorubicin. The patient toler-
ated the regimen better during the second cycle, and the 
PMH remained stable.
In July 2013, the patient underwent surgical resection 
to remove the right distal femoral lesion. DNA sequenc-
ing of the tumor revealed the presence of a tuberous scle-
rosis 1 (TSC1):c.1760A >Gp.K587R mutation. Owing to 
the TSC1 mutation, therapy with everolimus (10 mg/day) 
was started. Two months later, the patient underwent 
MRI of the pelvis, which revealed mild interval healing of 
the small intramedullary metastases in the supra-acetab-
ular region of the left iliac bone (Fig. 3).
Fig. 1 Imaging studies for 45‑year‑old patient (“Case 1”) with 
pseudomyogenic hemangioendothelioma. a Baseline fat saturated 
T1‑weighted axial magnetic resonance image with intravenous con‑
trast enhancement of the pelvis demonstrates multiple enhancing 
tumor foci in the right iliac bone (white arrow). b Positron emission 
tomography‑computed tomography (PET‑CT) fusion image through 
the pelvis demonstrates diffuse metabolic activity in the right anterior 
iliac bone (disease in the right posterior iliac bone at the level of the 
sacroiliac joint was also present but is not shown). This image was 
obtained 1 month before the patient began gemcitabine/docetaxel. 
c PET‑CT fusion image through the pelvis after three cycles of gemcit‑
abine/docetaxel demonstrates a significant metabolic response
Fig. 2 Baseline magnetic resonance imaging (MRI) and positron 
emission tomography‑computed tomography (PET‑CT) studies for 
a 22‑year‑old man (“Case 2”) with pseudomyogenic hemangioendo‑
thelioma. a Baseline contrast‑enhanced, fat‑saturated T1‑weighted 
axial MR image of the right thigh demonstrates multifocal enhanc‑
ing lesions in the distal femoral metadiaphysis (short white arrow) 
and vastus intermedius muscle and subcutaneous fat. b PET‑CT 
fusion image through the distal femurs demonstrates corresponding 
hypermetabolic activity. Restaging examinations after two cycles of 
gemcitabine and docetaxel (not shown) did not demonstrate any 
significant response
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Restaging MRI studies of the pelvis were performed 
5  months after the start of everolimus treatment and 
revealed generally stable disease and no evidence of 
recurrent disease in the thigh. Owing to the stability of 
the disease, the patient decided to cease everolimus ther-
apy and pursue cryotherapy. Overall, the mTOR inhibi-
tor provided a noticeable response in the tumor, which 
had not responded to doxorubicin and cisplatin. Thus, 
targeted therapy could serve as a viable treatment option 
for PMH.
Discussion
To the best of our knowledge, only two previous descrip-
tions of outcomes from PMH therapy other than resec-
tion have been published [5, 7]. The first report described 
a 36-year-old man with multiple lesions in his right lower 
leg treated with isolated limb perfusion (melphalan and 
tumor necrosis factor alpha) followed by four cycles 
of ifosfamide and doxorubicin. The treatment did not 
elicit significant shrinkage of the tumor, but the lesion 
remained stable after 9 months of follow-up [5]. The sec-
ond study reported a response of PMH to metronomic 
oral cyclophosphamide and prednisolone. The patient’s 
lesion decreased in size after 10 months of therapy before 
the patient became non-compliant; however, the report 
did not include any quantifiable data or imaging concern-
ing lesion size and progression [7].
A review of all published literature on pseudomyogenic 
hemangioendothelioma was performed to summarize 
major findings of this newly characterized soft tissue 
tumor. Of the 63 total reported cases, 78  % of patients 
were males. PMH presented in the extremities in 79 % of 
cases and was multifocal at diagnosis in over two-thirds 
of patients. 90  % of cases utilized excision as the treat-
ment modality of choice (Table 1).
In the first of our cases, the patient exhibited a notice-
able treatment response to gemcitabine plus docetaxel. 
As the 3  month follow-up PET-CT scans clearly indi-
cate, a significant tumor response was achieved following 
therapy (Fig. 1). The progression of the tumor 3 months 
after cessation of chemotherapy suggests that the tumor 
response directly resulted from the gemcitabine and doc-
etaxel therapy. Furthermore, the resumption of a taxane 
led to disease stability, suggesting that gemcitabine plus a 
taxane could be an effective treatment for PMH.
Unlike patient 1, patient 2’s tumor did not respond to 
gemcitabine plus docetaxel but ultimately showed sta-
bility following treatment with cisplatin and doxoru-
bicin. The differing outcomes following gemcitabine plus 
Fig. 3 Imaging studies obtained during treatment for a 22‑year‑old 
man (“Case 2”) with pseudomyogenic hemangioendothelioma. a 
Fat‑saturated T1‑weighted axial magnetic resonance image with 
intravenous contrast enhancement of the pelvis demonstrates a 
solitary enhancing tumor focus in the supra‑acetabular region of the 
left iliac bone (white arrow), before everolimus treatment. b Positron 
emission tomography‑computed tomography fusion image through 
the pelvis demonstrates corresponding metabolic activity. This image 
was obtained before the patient began everolimus treatment. c 
Fat‑saturated T1‑weighted axial MR image with intravenous contrast 
enhancement of the pelvis obtained after 2 months of everolimus 
demonstrates partial response of the solitary enhancing tumor focus 
in the supra‑acetabular region of the left iliac bone
Page 5 of 6Joseph et al. Clin Sarcoma Res  (2015) 5:22 
docetaxel treatment in the two cases reflect PMH’s heter-
ogeneity of response to cytotoxic chemotherapy. The dis-
covery of a TSC1 mutation in patient 2’s tumor prompted 
the use of an mTOR inhibitor. An mTOR inhibitor was 
selected due to its potential to inhibit aberrant mTOR 
signaling in perivascular epithelioid cell tumors with 
similar TSC1 mutations [8]. The mTOR inhibitor used 
in case 2 provided a noticeable response in the PMH 
metastases in the supra-acetabular region of the left 
iliac bone. Thus, systemic therapy targeted to the muta-
tions detected by DNA sequencing could be a promising 
option for PMH that warrants further investigation.
Conclusion
To the best of our knowledge, our report is the first to 
describe a response of PMH either to gemcitabine/
taxane chemotherapy or to an mTOR inhibitor. These 
observations are especially noteworthy because previous 
treatment options have typically dealt with local exci-
sion and a high rate of recurrence or chemotherapeutic 
approaches which lack a significant response. There is 
much to be learned about systemic treatment of pseu-
domyogenic hemagioendothelioma, but these two cases 
demonstrate two distinct treatment approaches that war-
rant further investigation.
Consent
Written informed consent was obtained from the patients 
for publication of this case report and any accompany-
ing images. A copy of the written consent is available for 
review.
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Table 1 Reported cases of pseudomyogenic hemangioendothelioma
a Patient 5 of this report was already accounted for in the series by Hornick et al. [2]
References Cases (N) Sex Tumor location Multifocality at diag-
nosis
Management
Sheng [1] 1 Male: 100 % (1of 1)
Female: 0 % (0 of 1)
Extremity: 100 % (1 
of 1)
100 % (1 of 1) Excision: 100 % (1 of 1)
Hornick and Fletcher 
[2]
50 Male: 82 % (41 of 50)
Female: 18 % (9 of 50)
Extremity: 78 % (39 
of 50)
Trunk: 18 % (9 of 50)
Head and neck: 4 % (2 
of 50)
66 % (33 of 50) Excision: 92 % (46 of 50)
Post‑operative radiation: 
16 % (8 of 50)
Chemotherapy: 12 % (6 
of 50)
Amary et al. [5] 5 (1 case included 
in Hornick was 
excluded)a
Male: 50 % (2 of 4)
Female: 50 % (2 of 4)
Extremity: 100 % (4 
of 4)
75 % (3 of 4) Excision: 75 % (3of 4)
Chemotherapy: 25 % 
(1 of 4)
Stuart et al. [7] 1 Male: 100 % (1 of 1)
Female: 0 % (0 of 1)
Extremity: 100 % (1 
of 1)
100 % (1 of 1) Chemotherapy: 100 % 
(1 of 1)
Sheng and Wang [9] 1 Male: 0 % (0 of 1)
Female: 100 % (1 of 1)
Extremity: 100 % (1 
of 1)
100 % (1 of 1) Excision: 100 % (1 of 1)
Requena et al. [10] 2 Male: 50 % (1 of 2)
Female: 50 % (1 of 2)
Extremity: 50 % (1 of 2)
Head and neck: 50 % 
(1 of 2)
100 % (2 of 2) Excision: 100 % (2 of 2)
Righi [11] 2 Male: 50 % (1 of 2)
Female: 50 % (1 of 2)
Extremity: 100 % (2 
of 2)
100 % (2 of 2) Excision: 100 % (2 of 2)
Karakasli et al. [12] 1 Male: 100 % (1 of 1) Extremity: 100 % (1 
of 1)
0 % (0 of 1) Excision: 100 % (1 of 1)
McGinity [13] 1 Male: 100 % (1 of 1)
Female: 0 % (0 of 1)
Extremity: 0 % (0 of 1)
Trunk: 100 % (1 of 1)
0 % (0 of 1) Excision: 100 % (1 of 1)
Total 63 Male: 78 % (49 of 63)
Female: 22 % (14 of 63)
Extremity: 79 % (50 
of 63)
Trunk: 16 % (10 of 63)
Head and neck: 5 % (3 
of 63)
Multifocality at diagno‑
sis: 68 % (43 of 63)
Excision: 90 % (57 of 63)
Post‑op radiation: 13 % 
(8 of 63)
Chemotherapy: 13 % (8 
of 63)
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